Zobrazeno 1 - 10 of 111 pro vyhledávání: '"Pravin T P, Kaumaya"'
1
Akademický článek
Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
Autor: Linlin Guo, Jay Overholser, Anthony J. Good, Nicholas J. Ede, Pravin T. P. Kaumaya
Publikováno v: Frontiers in Oncology, Vol 12 (2022)
Immunotherapy with monoclonal antibodies to checkpoint inhibitors against the PD-1/PD-L1 signaling pathway is a landmark achievement in cancer therapy. Some anti-PD-1 inhibitors such as nivolumab and pembrolizumab have shown clinical success, in a pe
Externí odkaz: https://doaj.org/article/3c90062cf7a34c32a9406f9facbef1a0
Zobrazit plný text záznamu
2
Akademický článek
Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
Autor: Pravin T. P. Kaumaya, Linlin Guo, Jay Overholser, Manuel L. Penichet, Tanios Bekaii-Saab
Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients a
Externí odkaz: https://doaj.org/article/c3d50d157aeb4a1bb55b4e175f6f0ae6
Zobrazit plný text záznamu
3
Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
Autor: Linlin Guo, Jay Overholser, Anthony J. Good, Nicholas J. Ede, Pravin T. P. Kaumaya
Publikováno v: Frontiers in oncology. 12
Immunotherapy with monoclonal antibodies to checkpoint inhibitors against the PD-1/PD-L1 signaling pathway is a landmark achievement in cancer therapy. Some anti-PD-1 inhibitors such as nivolumab and pembrolizumab have shown clinical success, in a pe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1c5140799da132ab554c6a792cb94b0
https://pubmed.ncbi.nlm.nih.gov/35646678
Zobrazit plný text záznamu
4
First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations
Autor: Pravin T. P. Kaumaya, Linlin Guo
Publikováno v: Br J Cancer
We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84a3f869c5d033267addb0f3f8e96bc9
https://doi.org/10.1038/s41416-021-01342-9
Zobrazit plný text záznamu
5
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Autor: Robert Wesolowski, Maryam B. Lustberg, Jay Overholser, Bhuvaneswari Ramaswamy, Christina Wu, Tanios Bekaii-Saab, Pravin T. P. Kaumaya, Lai Wei, Daniel H. Ahn, Amir Mortazavi, Jeffrey M. Fowler
Publikováno v: Clin Cancer Res
Purpose: This first-in-human phase I study (NCT 01417546) evaluated the safety profile, optimal immunologic/biological dose (OID/OBD), and immunogenicity of the combination of two peptide B-cell epitope vaccines engineered to represent the trastuzuma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::850069af380711879b5bd4b2142692e9
https://doi.org/10.1158/1078-0432.ccr-18-3997
Zobrazit plný text záznamu
7
Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
Autor: Manuel L. Penichet, Jay Overholser, Pravin T. P. Kaumaya, Tanios Bekaii-Saab, Linlin Guo
Publikováno v: Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 9, Iss 1 (2020)
Therapeutic blockade of PD-1/PD-L1 signaling with monoclonal antibodies (mAbs) has shown clinical success and activity across a broad set of cancer subtypes. However, monotherapy with PD-1/PD-L1 inhibitors are only effective in a subset of patients a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ba9715063ac68aa9717df7e1387fe8
http://europepmc.org/articles/PMC7553530
Zobrazit plný text záznamu
8
B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine
Autor: Pravin T. P. Kaumaya
Publikováno v: Future Oncology
In light of the numerous US FDA-approved humanized monoclonal antibodies (mAbs) for cancer immunotherapy, it is surprising that the advancement of B-cell epitope vaccines designed to elicit a natural humoral polyclonal antibody response has not gaine
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4860740a5afc652d9a5d963522c604a9
https://doi.org/10.2217/fon-2020-0224
Zobrazit plný text záznamu
9
Abstract CT128: IMU-201-101 - an open-label, multi-center, dose escalation/expansion, phase 1 study of IMU-201 (PD1-Vaxx), a B-cell immunotherapy, in adults with non-small cell lung cancer
Autor: Anthony J Good, Nick Ede, Mark T. Marino, Tanios Bekaii-Saab, Pravin T. P. Kaumaya, Tri Giang Phan
Publikováno v: Cancer Research. 80:CT128-CT128
Background: The inhibitory immune pathway, consisting of the receptor programmed cell death 1 (PD-1) and its ligands, PD-L1 and PD-L2, plays a vital role in the maintenance of peripheral tolerance. Therapies with monoclonal antibodies targeting PD-1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44ca32fa84405b4fb84ed4fd38c2a863
https://doi.org/10.1158/1538-7445.am2020-ct128
Zobrazit plný text záznamu
10
Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs
Autor: Manuel L. Penichet, B. Sayanjali, Yuanquan Yang, T. S. Bekaii-Saab, Pravin T. P. Kaumaya, L. Chong, Linlin Guo, N. Ede, Jay Overholser
Publikováno v: Annals of Oncology. 30:v497-v498
Background Anti-PD-1 blocking monoclonal antibodies (mAbs) such as nivolumab or pembrolizumab have shown potent anti-tumor effects in different metastatic cancers. Similarly, anti-HER-2 mAbs such as Herceptin and Perjeta are approved for breast cance
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8209093cd415ec78b176b4a329d5fbf
https://doi.org/10.1093/annonc/mdz253.044
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje